Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319123 | 0.84 | CES2 (0.62) | CES2CES1CA5AHCAR1LMNA | |
| SCHEMBL15709749 | 0.84 | CA5A (0.52) | CES2CES1CA5ANOTUMLMNA | |
| SCHEMBL343284 | 0.84 | CA5A (0.52) | CES2CES1CA5ANOTUMLMNA | |
| SCHEMBL16952349 | 0.80 | CES2 (0.36) | CES2CES1HCAR1NOTUM | |
| SCHEMBL560207 | 0.80 | HCAR1 (0.59) | CES2CES1CA5AHCAR1LMNA | |
| SCHEMBL29759213 | 0.80 | HCAR1 (0.59) | CES2CES1CA5AHCAR1LMNA | |
| SCHEMBL15587366 | 0.79 | CES2 (0.41) | CES2CES1HCAR1NOTUMALDH1A1 | |
| Hydrochloric Acid SCHEMBL5226036 | 0.78 | HCAR1 (0.57) | CES2CES1CA5AHCAR1LMNA | |
| SCHEMBL5225361 | 0.78 | CES2 (0.44) | CES2CES1HCAR1NOTUMALDH1A1 | |
| SCHEMBL12607365 | 0.78 | PARP1 (0.50) | CES2CES1HCAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0195396-B1 | 5-FLUOROBENZONITRILE DERIVATIVES AND PHARMACOLOGICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF FOR INCREASING THE LEAN MEAT TO FAT RATIO, AND/OR ENHANCING THE GROWTH RATE OF WARM-BLOODED ANIMALS | AMERICAN CYANAMID COMPANY (US) | 1989-03-01 | — | — | EP | claimed |
| EP-0195396-A1 | 5-Fluorobenzonitrile derivatives and pharmacologically acceptable acid addition salts thereof for increasing the lean meat to fat ratio, and/or enhancing the growth rate of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1986-09-24 | — | — | EP | claimed |
| WO-2025264844-A1 | HETEROCYCLIC GPR52 MODULATORS AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250059175-A1 | Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2025-02-20 | — | — | US | disclosed |
| WO-2025038815-A1 | MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025038462-A2 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025014200-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 티움바이오 | 2025-01-16 | — | — | WO | disclosed |
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-12-26 | — | — | US | disclosed |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| CN-118344342-A | Substituted polyaromatic ring derivatives, compositions and uses thereof | 康迈迪森(北京)医药科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-4330246-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | Ontario Institute for Cancer Research (OICR) (CA) | 2024-03-06 | — | — | EP | disclosed |
| EP-1506190-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003097637-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
| EP-0735142-B1 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICALS CO LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0195396-B1 | 5-FLUOROBENZONITRILE DERIVATIVES AND PHARMACOLOGICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF FOR INCREASING THE LEAN MEAT TO FAT RATIO, AND/OR ENHANCING THE GROWTH RATE OF WARM-BLOODED ANIMALS | AMERICAN CYANAMID COMPANY (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4614746-A | 5-fluorobenzonitrile derivatives for increasing the lean meat to fat ratio and/or enhancing the growth rate of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1986-09-30 | — | — | US | disclosed |
| EP-0195396-A1 | 5-Fluorobenzonitrile derivatives and pharmacologically acceptable acid addition salts thereof for increasing the lean meat to fat ratio, and/or enhancing the growth rate of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1986-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059175-A1 | Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals | PIK3CA, PIK3CD, PIK3R5 | CES2 2358/4885CES1 745/4885CA5A 2898/4885 |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | GRIN2B, GRIN2A, GRIN2C | CES2 4238/4885CES1 4411/4885CA5A 2118/4885 |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | CES2 4359/4885CES1 2407/4885CA5A 4372/4885 |
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | DCK, CMPK1, WNK1 | CES2 3804/4885CES1 1693/4885CA5A 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.